Saturday, August 12, 2017

FDA approves two drugs for certain types of AML

A scanning electron 
microscope image 
from normal circulating 
human blood. – Wikipedia

CANCER DIGEST – Aug. 12, 2017 – The FDA approved two new drugs for treatment of specific types of acute myeloid leukemia (AML), a rapidly progressing cancer that forms in the bone marrow.

Vyxeos was approved for two types of AML, newly diagnosed therapy-related AML called t-AML, and myelodysplasia-related changes changes called ALM-MRC. 

Monday, August 7, 2017

Targeted radiotherapy reduces side effects of breast cancer surgery


CANCER DIGEST – Aug. 7, 2017 – Targeting the tumor site with radiotherapy after surgery to remove breast cancer resulted in fewer long-term side effects five years later, according to a new British study.

The researchers at 30 radiotherapy centers across the UK, led by The Institute of Cancer Research, London, and the Cancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of coming back. The results of the study were published in the Aug. 2, 2017 The Lancet.